

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

Oncology

Drug class	Platform	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Rights/Colaborator
mRNA	FixVac	BNT111	Advanced and R/R melanoma	█	█	█		Fully owned
		BNT112	Prostate cancer	█	█			
		BNT113	HPV16+ head and neck cancer	█	█	█		
		BNT116	2L NSCLC	█				
	iNeST	Autogene cevumeran (BNT122)	1L advanced melanoma	█	█	█		Genentech ² (global 50:50 profit/loss share)
			Adjuvant colorectal cancer	█	█	█		
			Multiple solid tumors	█				
	Intratumoral immunotherapy	BNT131 (SAR441000)	Multiple solid tumors (IL-12sc, IL15-sushi, GM-CSF, IFNα)	█				Sanofi (global profit/loss share)
	RiboMabs	BNT141	Multiple solid tumors (CLDN18.2)	█	█	█		Fully owned
		BNT142	Multiple solid tumors (CD3×CLDN6)	█	█	█		
RiboCytokines	BNT151	Multiple solid tumors (IL-2 variant)	█	█	█		Fully owned	
	BNT152, BNT153	Multiple solid tumors (IL-7, IL-2)	█					
Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)	█	█	█		Fully owned
	Neoantigen-based T cells	BNT221	Advanced and R/R melanoma	█				Fully owned
Protein-based therapeutics	Next-generation immune checkpoint modulators	BNT311 (GEN1046)	Metastatic NSCLC (PD-L1×4-1BB)	█	█	█		Genmab (global 50:50 profit/loss share)
		Multiple solid tumors (PD-L1×4-1BB)	█	█	█			
		BNT312 (GEN1042)	Multiple solid tumors (CD40×4-1BB)	█	█	█		
		BNT313 (GEN1053)	Multiple solid tumors (CD27)	█	█	█		
		BNT322 (GEN1056)	Multiple solid tumors (undisclosed)	█				
	Targeted cancer antibodies	BNT316 (ONC-392)	Platinum-resistant ovarian cancer (CTLA-4)	█	█	█		OncoC4 (exclusive global license)
		Multiple solid tumors (CTLA-4)	█	█	█			
Antibody-drug conjugates	BNT321	Pancreatic cancer (sLea)	█				Fully owned	
	BNT323 (DB-1303)	Multiple solid tumors (HER2)	█	█	█		Duality Bio (exclusive global license excluding Mainland China, Hong Kong SAR, and Macau SAR)	
SMIM ³	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)	█	█	█		Fully owned

Infectious Diseases

Drug class	Indication	Product candidate	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	Rights/Colaborator
mRNA	COVID-19	COMIRNATY	█	█	█	█	█	Pfizer (global marketing and distribution rights, excl. Germany, Türkiye, Mainland China, Hong Kong SAR, Macau SAR and Taiwan region) Fosun Pharma (marketing and distribution rights in Mainland China, Hong Kong SAR, Macau SAR and Taiwan region)
		BNT162b2(Original/Omicron BA.4-5-adapted bivalent)	█	█	█	█	█	
		BNT162b2 (Original/Omicron BA.1-adapted bivalent)	█	█	█	█	█	
		BNT162b4 (T-cell enhancing)	█					
		BNT162b5 (Enhanced spike antigen)	█	█	█			
	COVID-19 – Influenza combination	BNT162b2+BNT161 (qFlu + BA.4-5-adapted bivalent) ⁴	█					
	Influenza	BNT161	█	█	█	█		Exclusive license to Pfizer
	Shingles	BNT167	█	█	█			Partnered with Pfizer globally
	HSV-2	BNT163	█					Collaboration with University of Pennsylvania
	Tuberculosis	BNT164 ⁵	█					Collaboration with Bill & Melinda Gates Foundation
Malaria	BNT165	█					Fully owned	

¹ Investigator initiated trial

² A member of the Roche group

³ Small Molecule Immunomodulators

⁴ The COVID-19-Influenza combination is a Phase 1 trial in partnership with Pfizer. Further development is subject to reaching agreement.

⁵ BioNTech holds worldwide distribution rights except developing countries where Bill & Melinda Gates Foundation holds distribution rights